The Effects of Drug Candidate CS1 on Lung Structure and Function Utilizing FRI

Explore the impact of drug candidate CS1 on pathological vascular remodeling of small pulmonary arteries in the disease pulmonary arterial hypertension (PAH). This sub-study for CS1-004 aims to utilize FRI, an innovative, non-invasive imaging technology to visualize how long-term use of CS1 influences structural changes in pulmonary arteries. This sub-study seeks to provide valuable insights into the potential of CS1 to transform PAH treatment in some patients enrolled in the Expanded Access Program (CS1-004).

NCT Number	NCT06907693
Lead Sponsor	Prisma Health-Upstate Collaborators: Cereno Scientific AB
Conditions	Pulmonary Arterial Hypertension
Enrollment	7 participants
Start Date	2025-03-14
Primary Completion	2025-12-04 (estimated)
Study Completion	2026-04-09 (estimated)
Updated on ClinicalTrials.gov	2026-04-13